Management of hyperphosphataemia in XXXX -challenges and solutions.

@entity1 @entity4613 @entity11648 @entity740 @entity729 @entity65
Hyperphosphataemia is a clinical consequence of the advanced stages of @entity740 ( @entity740 ). Considerable evidence points to a role of hyperphosphataemia in the pathogenesis of @entity740 -associated @entity65 , including @entity729 , and with increased all-cause and CV mortality. These observations place management of hyperphosphataemia at the centre of @entity740 treatment. Although our increased understanding of the physiological role of @entity11648 may provide a long-term alternative biomarker of @entity4613 load and underlying disease progression, regular determination of serum @entity4613 is currently the most frequently used parameter to evaluate @entity4613 load in clinical practice. This review considers the challenges physicians and @entity1 face in trying to control hyperphosphataemia. Amongst these are the limitations of dietary @entity4613 restriction, giving rise to the need for @entity4613 binder therapy to maintain serum @entity4613 control. Once the decision to use @entity4613 binders has been made, considerations include the relative efficacy, different potential side effects and pill burden associated with various @entity4613 binders. Although a number of @entity4613 binders are available, adherence poses a major obstacle to effective treatment. This emphasizes that further improvements to @entity4613 binder therapy can be made. Evaluation of novel agents and their potential role in the clinic should continue.
